Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

被引：0
|
作者：
Jamaal L. James
Justin M. Balko
机构：
[1] Vanderbilt University Medical Center,Department of Medicine
[2] Vanderbilt University Medical Center,Cancer Biology Program
[3] Vanderbilt University Medical Center,Department of Pathology, Microbiology and Immunology
[4] Vanderbilt University Medical Center,Breast Cancer Research Program
来源：
Current Breast Cancer Reports | 2019年 / 11卷
关键词：
Breast cancer; Biomarkers; Programmed death-ligand 1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：217 / 227
页数：10
相关论文
共 50 条
  • [21] PD-L1 assessment in breast cancer immunotherapy: a critical overview
    Ricci, Angela Dalia
    Rizzo, Alessandro
    Palmiotti, Gennaro
    Brandi, Giovanni
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 58 - 59
  • [22] Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
    Noguchi, Emi
    Shien, Tadahiko
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 321 - 332
  • [23] PD-L1 protein expression is a prognostic biomarker in breast cancer
    Wimberly, H.
    Schalper, K.
    Chen, L.
    Velcheti, V.
    Pusztai, L.
    Rimm, D.
    CANCER RESEARCH, 2013, 73
  • [24] Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment
    Miles, J.
    Gumuzio, J.
    Calleja, V.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S99 - S100
  • [25] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
    Gumuzio, Juan
    Calleja, Veronique
    Miles, James
    Sancehz-Magraner, Lissete
    Aguirre, Fernando
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [26] Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells
    Silva, Manuel A.
    Triltsch, Nicolas
    Leis, Simon
    Kanchev, Ivan
    Tan, Tze Heng
    Van Peel, Benjamine
    Van Kerckhoven, Marian
    Deschoolmeester, Vanessa
    Zimmermann, Johannes
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 124 - 137
  • [27] PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
    Zhou, Zi-Qi
    Zhao, Jing-Jing
    Pan, Qiu-Zhong
    Chen, Chang-Long
    Liu, Yuan
    Tang, Yan
    Zhu, Qian
    Weng, De-Sheng
    Xia, Jian-Chuan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [28] The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors
    Nuvola, Giacomo
    Mollica, Veronica
    Massari, Francesco
    Suarez, Cristina
    IMMUNOTHERAPY, 2023, 15 (17)
  • [29] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
    Pizon, M.
    Schott, D.
    Pachmann, U.
    Pachmann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
  • [30] GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer
    Sun, Xue
    Lin, Mingen
    Tian, Ziyin
    Ma, Yan
    Lv, Lei
    HELIYON, 2024, 10 (07)
12345